Musings from The Power List: Renee Aguiar-Lucander
Renee Aguiar-Lucander argues that faster clinical trials and more pragmatic regulation are essential to bringing medicines to patients sooner
False
Renee Aguiar-Lucander argues that faster clinical trials and more pragmatic regulation are essential to bringing medicines to patients sooner
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
False
False
October 8, 2026
4 min read
We asked the 2026 Power List whether newer modalities have eclipsed small molecules – and where the traditional mainstay still wins
October 5, 2026
4 min read
Regeneron's L. Andres Sirulnik explains why modernizing clinical trials is as important as developing new medicines
October 2, 2026
5 min read
We asked the 2026 Power List how the pharmaceutical industry can prepare for geopolitical, economic, regulatory, and scientific uncertainty
October 1, 2026
3 min read
Cellares Co-Founder and CEO discusses why the future of cell therapy depends on rethinking how therapies are made
False
Affiliations:
Specialties:
Areas of Expertise: